StreetAlpha.app
Home › Stocks › BIOA

BioAge Labs, Inc. (BIOA)

Healthcare
$5.10
▼ −2.30%
LAST CLOSE · NOV 17

BioAge Labs develops drug candidates for cardiometabolic diseases, using human aging biology to identify its drug targets. It last closed at $5.10 on Nov 17, down 2.30% on the day. The average 12-month price target from 3 analysts is $24.33 (+377.1% from the last close), with a high of $40.00 and a low of $8.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).

AI Auto Pilots
Is BIOA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$8.6M
+45.3% vs a year ago
Net income
−$107.8M
−1253.6% margin
EPS (diluted)
−$2.56
−118.8% vs a year ago
Free cash flow
−$103.0M
−1197.8% margin
Valuation
Market cap
$234.4M
46.0M shares
P/E
–
No P/E while losing money
Price to sales
27.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$52.7M
At Sep 30
Shareholder equity
$346.4M
Shares outstanding
46.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $9.0M$9.0MFY2025

From BIOA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
3firms
2 Buy1 Hold0 Sell
Each firm's latest rating on BIOA in the past 90 days
Average 12-month target
$24.33
▲ 377.1% upside

Based on 3 analysts who set a price target on BIOA in the past 90 days. The average target is $24.33, with a high of $40.00 and a low of $8.00, compared with the last close of $5.10.

Low $8.00Avg $24.33High $40.00
Blue marker: last close $5.10
Highest target$40.00
Average target$24.33
Lowest target$8.00
Latest rating changes
Piper SandlerMaintained
Nov 9Buy$40
UBSInitiated
Oct 12Hold$8
Roth CapitalTarget lowered
Sep 9Buy$36 → $25
BTIGReiterated
Aug 3Buy$40
NeedhamMaintained
Jul 31Buy$35
DateFirmActionRatingPrice target
Nov 9Piper SandlerMaintainedBuy$40
Oct 12UBSInitiatedHold$8
Sep 9Roth CapitalTarget loweredBuy$36 → $25
Aug 3BTIGReiteratedBuy$40
Jul 31NeedhamMaintainedBuy$35
Loading…

Technical Analysis

BIOA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 10% below its 20 day and 26% below its 50 day average. It is 194% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the Pivot S1 at $4.97, and the nearest resistance the Pivot at $5.14.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 8.4%/day
Key levels
$25.9652 week high+409.0%
$14.97200 day average+193.5%
$11.31100 day average+121.8%
$6.4350 day average+26.1%
$5.70Swing high (Oct 21)+11.8%
$5.5920 day average+9.6%
$5.27Pivot R1+3.3%
$5.14Pivot+0.8%
$5.10Last close
$4.97Pivot S1−2.5%
$4.92Swing low (Oct 26)−3.5%
$4.8152 week low−5.7%
Indicators
RSI (14)35.78Weak, oversold below 30Neutral
MACD-0.30Above its signal lineBullish
Stochastic22.1Middle of its rangeNeutral
ADX (14)22.4Weak trend
Williams %R-92.4Oversold below −80, overbought above −20Oversold
CCI (20)-128.5Oversold below −100, overbought above 100Oversold
Rate of change−14.4%Change over 10 sessionsBearish
ATR (14)$0.43Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BIOA

What happened before

See how BIOA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in BIOA in the last 90 days.

Loading…

See today’s whale options flow across the market →

BIOA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲98 buying vs 81 selling
  • ▼Held by funds -3.8 pts
  • ▲Funds holding +11
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162151+7.3%
In funds' top 1027−71.4%
Held by funds78.3%82.1%−3.8 pts
New / increased46 / 5228 / 60+11.4%
Reduced / sold out46 / 3540 / 19+37.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BIOA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIOA is in one of them and how their past BIOA trades turned out.

BIOA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BIOA in an article yet. Here's the latest on the wider market.

About BioAge Labs

BioAge Labs is a biopharmaceutical company based in Emeryville, California, that develops drug candidates for chronic cardiometabolic diseases such as heart disease, diabetes and obesity. Its approach uses human datasets from long-term biobanked samples and health records to find biological pathways linked to aging. Its lead candidate, BGE-102, is an oral NLRP3 inhibitor being studied for cardiovascular risk and diabetic macular edema. The company is also developing apelin receptor agonists for obesity and works with Eli Lilly and Novartis on earlier stage programs.

Headquarters
Emeryville, CA